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Abstract
Introduction: Studies have shown that fetal progenitor cells persist in maternal blood or bone marrow for more
than 30 years after delivery. Increased trafficking of fetal cells occurs during pregnancy complications, such as
hypertension, preeclampsia, miscarriage and intra-uterine growth restriction (IUGR). Women with these pregnancy
complications are significantly more often HLA-class II compatible with their spouses. Women who later develop
scleroderma also give birth to an HLA-class II child more often. From these prior studies we hypothesized that
preeclampsia and other pregnancy complications could be associated with increased levels of fetal cell trafficking,
and later be involved in the development of scleroderma.
Methods: This study was a retrospective multi-centre matched case-control study. One-hundred-and-three women
with systemic sclerosis (SSc) and 103 women with no history of SSc or other autoimmune disease were given a
questionnaire regarding complications during pregnancy, such as hypertension, intra-uterine growth restriction
(IUGR) and miscarriage. Conditional logistic regression analysis was used to assess associations.
Results: We found a statistically significantly increased incidence of having had a pregnancy history of
hypertension or a fetus with IUGR in women who subsequently developed SSc compared to healthy controls. We
found an odds ratio of 2.6 (95% confidence interval (CI): 1.1 to 4.6) for hypertensive complications during
pregnancy and an odds ratio of 3.9 (95% CI: 1.2 to 12.3) for intra-uterine growth restriction for women with SSc
compared to healthy controls.
Conclusions: This is the first study to show an association between hypertensive complications during pregnancy
or IUGR and the development of SSc at a later age. We speculate that the pregnancy abnormalities may have
resulted in increased fetomaternal trafficking, which may have played a role in the increased incidence of SSc.
Further studies are indicated to examine this putative relationship.
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Introduction
Systemic sclerosis (SSc) is a connective tissue disease of
unknown origin that is characterized by cutaneous and
visceral fibrosis, production of auto-antibodies, and pro-
minent microvascular changes. The similarities of this
autoimmune disease to graft versus host disease, which
is an iatrogenic form of chimerism, have suggested a
common pathway in the pathogenesis of both diseases
[1].
Increased trafficking of fetal cells into maternal circu-
lation occurs with pregnancy complications such as pre-
eclampsia [2-4]. In preeclampsia, deficient invasion of
cytotrophoblasts results in insufficient modification of
the maternal spiral arteries. This failure leads to placen-
tal hypoxia and placental lesions, which possibly result
in increased trafficking of fetal cells into the maternal
circulation. Prior studies have shown that fetal DNA
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by intrauterine growth restriction (IUGR), pregnancy
induced hypertension and hemolysis elevated liver func-
tion low platelet (HELLP) syndrome. As a result of
spontaneous miscarriage and after induced abortion,
fetomaternal cellular trafficking is also increased
[2,3,5-9]. The term microchimerism (MC) refers to the
presence of a small population of cells in one individual
that have been derived from another genetically distinct
person. Well known causes of MC are blood transfu-
sion, transplantation and pregnancy [1]. There is evi-
dence that cells pass through and across the placenta
during pregnancy, from mother to fetus and vice versa.
Studies have shown that fetal progenitor cells persist in
maternal blood or bone marrow for more than 30 years
after delivery [10-12].
The increased incidence of autoimmune disease in
women after childbearing years, the long-term persis-
tence of fetal progenitor cells in maternal blood and
similarities between certain autoimmune diseases and
graft versus host disease, have led to the hypothesis that
fetal cell microchimerism is somehow involved in the
pathogenesis of some forms of autoimmune disease [13].
Male (presumed fetal) DNA and intact cells have been
detected more often in the circulating blood and skin of
women with SSc as compared to healthy women [5,14].
Several reports have shown that women with pree-
clampsia and pregnancy induced hypertension are statis-
tically significantly more often HLA-class II compatible
with their spouses as compared to women with uncom-
plicated pregnancies [15]. Women who later develop
SSc also give birth to an HLA-class II compatible child
more often than healthy women [14,16].
We, therefore, hypothesized that pregnancy complica-
tions (for example, PIH, PE, IUGR, miscarriage) could
be associated with increased levels of fetal cell traffick-
ing and could later be involved in the development of
scleroderma. In order to assess this relationship, we per-
formed a preliminary study to explore such a hypothesis.
Materials and methods
This retrospective multi-centre matched case-control
study was performed at Leiden University Medical Cen-
tre (LUMC) and the VU Medical Centre of Amsterdam
(VUMC) in the Netherlands. This study was approved
by the Medical-Ethical Board of the LUMC.
Study subjects
A total of 103 cases were recruited from the rheuma-
tology departments of the LUMC and the VUMC. All
cases were women with a diagnosis of SSc after their
pregnancies had been completed and who had been
pregnant at least once. One hundred and three healthy
controls with no history of autoimmune disease were
recruited from two different general practitioners’
clinics in Venhuizen and Noordwijk, The Netherlands.
Cases and controls were matched on age (± 5 years)
and number of pregnancies (primiparous vs.
multiparous).
Study method
All women received detailed study information and a
questionnaire. Informed consent was obtained from all
cases and controls. Baseline characteristics, such as
maternal age, weight and height, as well as smoking
habits during pregnancy and total number of pregnan-
cies were obtained via the questionnaire. Information on
the subject’s obstetric history, including the sex of their
children, and complications during pregnancy was
obtained. Women were asked if they had hypertensive
complications during pregnancy, such as pregnancy-
induced hypertension (PIH) or preeclampsia (PE)
(hypertension and proteinuria). Information on the use
of anti-hypertensive medication and hospital admission
during pregnancy, fetal IUGR and fetal death (miscar-
riage) was also obtained through the questionnaire.
IUGR was defined as abnormal growth of the fetus in
utero.
Statistical analysis
Assuming that the incidence of preeclampsia, PIH and
IUGR was 25% in the cases and 5% in the controls [17],
the power analysis indicated that 110 women in each
category were needed to be included so that a power of
0.80 could be reached (a = 0.05). Based on an expected
response rate of 80%, 280 questionnaires were sent out
by mail to cases (n = 140) and controls (n = 140).
Baseline characteristics of the cases and controls were
compared using the Student t-test for means and Chi-
square for proportions using SPSS 16.0 (SPSS Inc. Chi-
cago, USA). A conditional logistical regression analysis
was used to calculate odds ratios between the cases and
the matched controls.
Results
The response rates to the questionnaire for the cases
and controls were 70% and 74%, respectively. There
were no differences in demographic characteristics
between cases and controls (Table 1). The mean differ-
ence between the age at the first pregnancy and the
onset of scleroderma was 27.4.
There was a statistically significant association
between both hypertensive complications and fetal
growth restriction with the development of SSc in later
life. Non-statistically significant trends were found in
women who experienced miscarriage and those who
used anti-hypertensive medication during pregnancy and
later developed SSc (Table 2).
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This preliminary study showed a significant difference in
the occurrence of hypertensive complications during
pregnancy in women who later developed SSc compared
to healthy parous women. There was also a significantly
increased incidence of fetal growth restriction in the
cases. This is the first study to demonstrate an associa-
tion between a history of hypertensive complications
during pregnancy or IUGR and the development of SSc
after childbearing age. The same trend, although not
statistically significant, was found for the reported use of
anti-hypertensive medication during pregnancy or a his-
tory of miscarriage.
The association between hypertensive complications
during pregnancy and/or IUGR and subsequent SSc at a
later age could possibly be explained by a number of
factors. Pregnancy complications, such as hypertension
and IUGR, are associated with increased fetal-maternal
trafficking [2-4]. Women with SSc, and women with
hypertensive complications during pregnancy, are more
often HLA-class II compatible with their spouses than
controls [18]. Greater tissue antigen compatibility
between the pregnant woman and her fetus could also
help to explain why fetal cells can persist in the mater-
nal system and can be detected in the mothers’ blood
and organs for decades post-partum [5,10-12,14]. The
similarities between SSc and graft-versus host disease
suggests that the pathogenesis of the two diseases might
have some similarities. Possibly, pregnancy
complications and HLA-class II compatibility lead to
increased fetomaternal cell trafficking, which at a later
age might be involved in the pathogenesis of SSc. An
alternate explanation could be that women who are
later destined to develop SSC could already have a sub-
clinical form of the disease during pregnancy affecting
placental development, which then results in pregnancy
complications, such as IUGR and hypertension.
In this study, we obtained information about the sub-
jects’ obstetric history by using retrospective question-
naires. Our conclusions are based on the information
provided by the research subjects, which is inherently
subjective. A more objective approach would have been
to review all of the medical records concerning the
obstetrical histories for the cases and controls, but this
was not possible due to loss of patient files related to
the relatively long interval between pregnancy and the
development of SSc. Another bias that could affect the
results is that in the control group, women with a his-
tory of complications during pregnancy could have been
more likely to respond to the questionnaire than women
with no history of pregnancy complications. However,
this potential bias could only result in an underestima-
tion of the association between pregnancy complications
and SSc. In addition, patients with a history of sclero-
derma may recall their medical histories in more detail
than controls, which could have led to an overestima-
tion of the studied pregnancy complications. On the
other hand, on average, more than two decades passed





Mean Difference (95% CI*) or P-value
Age (mean) years 57.7 57.2 0.5 (-3.6; 2.7)
Mean age at first pregnancy 25.6 26.1 -0.5 (-1.0; 1.9)
Mean age at diagnosis (SSc**) 53.0
# NA NA
Body Mass Index during first pregnancy 22.2 22.7 -0.5 (-1.4; 0.3)
Sex of children Male 30% (31) 19.4% (20) 0.1
Female 16.5% (17) 22.3% (23) 0.4
Both 47.5% (49) 57.3% (59) 0.2
Number of pregnancies Mean 2.46 2.41 0.1 (-0.3; 0.2)
Primipara 13.6% (14) 13.6% (14) 1.0
Multipara 86.4% (89) 86.4% (89) 1.0
Smoking during pregnancy (% yes) 18% (18.5) 22% (23) 0.5
*CI, confidence interval; **SSc, systemic sclerosis;
#n = 61 (59.2%), data not complete for all cases
Table 2 Comparison of obstetric information of the cases and their matched controls
Characteristic Cases (%) Controls (%) P-value Odds Ratio (95% CI*)
Hypertensive complications during pregnancy 26.5% 13.7% 0.03 2.6 (1.1 to 4.6)
Medication use for high blood pressure 8.8% 3.9% 0.16 2.4 (0.7 to 7.9)
IUGR** 13.7% 3.9% 0.02 3.9 (1.2 to 12.3)
Miscarriage 32.7% 21.6% 0.08 1.8 (0.9 to 3.3)
*CI, confidence interval; **IUGR, intra uterine growth restriction.
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scleroderma; therefore, this bias is most likely minimal.
Conclusions
In summary, the results of this preliminary study show
that in women who later developed SSc, there was an
increased incidence of pregnancy complications, such as
hypertension and IUGR. Future studies are indicated to
more fully explore this relationship, including its possi-
ble association with fetomaternal microchimerism.
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